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Renal neuronal nitric oxide synthase protein expression as a
marker of renal injury.
Background. Animal studies suggest that nitric oxide defi-
ciency occurs in the remnant after 5/6 removal of renal mass.
The present studies investigated the time course in relation to
progression of renal disease, as well as the impact on individual
renal nitric oxide synthase (NOS) isoforms.
Methods. Rats were studied from 2 to 11 weeks after 5/6
ablation/infarction (A/I) of renal mass, with acceleration of
progression by high protein and salt intake, in some groups.
Measurements were made before sacrifice of 24-hour protein
and creatinine excretion, blood was taken for creatinine and
blood urea nitrogen (BUN) determination and the kidneys
were investigated histologically for structural damage, abun-
dance of endothelial NOS (eNOS) and neuronal NOS (nNOS),
and in some groups for in vitro NOS activity.
Results. A time-dependent fall in glomerular filtration rate
(GFR) and rise in proteinuria and glomerular sclerosis devel-
oped after 5/6 A/I. The nNOS abundance in cortex and medulla
was decreased relative to shams, in all but the mildest injury
and there was a strong, steep correlation between level of
glomerular sclerosis and the degree of reduction in renal nNOS.
Where measured, cortical NOS activity correlated with the
nNOS abundance. In contrast, the eNOS abundance was either
increased or unchanged in rats post A/I.
Conclusion. Renal nNOS adundance was reduced in the 5/6
A/I model of renal disease when plasma creatinine1 mg/dL
and when 20% of remaining glomeruli were sclerosed.
There is good evidence that overall nitric oxide defi-
ciency occurs in end-stage renal disease (ESRD) in man
and in chronic renal disease (CRD) in humans and ani-
mals [1–6]. Furthermore, it is possible that the nitric
oxide deficiency is pathogenic and contributes to further
progression of the CRD, since chronic dietary arginine
[nitric oxide synthase (NOS) substrate] supplementation
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is renoprotective in rat models of CRD, including renal
ablation [7–10]. Also, chronic inhibition of nitric oxide
synthesis increases blood pressure and causes CRD in
otherwise healthy rats [11] and accelerates the progres-
sion of CRD when superimposed on the 5/6 renal abla-
tion/infarction (A/I) model [12]. Possible mechanisms
for widespread inhibition of nitric oxide production in
CRD include the accumulation of circulating NOS inhib-
itors and/or reduced intracellular substrate availability
[13, 14]. There is also evidence of a localized decline in
renal NOS activity in two different models of CRD, due
both to renal mass reduction [4] and chronic glomerulo-
nephritis [6]. Several groups have reported declines in
the abundance of NOS protein in the remnant kidney,
with falls in inducible NOS (iNOS) and variable falls in
endothelial NOS (eNOS) being reported [4, 15–18]. The
findings with the neuronal NOS (nNOS) are more vari-
able, with a marked and early decline [5] as well as an
increased abundance [5, 17] having been reported by
different groups.
Because the renal mass reduction models are rapidly
progressing, are inherently variable in the individual rate
of progression, and are likely to vary between labora-
tories, we investigated the renal NOS system in this
model over a range of severity, from 2 to 11 weeks
post 5/6 A/I, and, in some animals, we accelerated the
development of uremia by combining 5/6 A/I with high
protein intake and NaCl loading. The goal was to deter-
mine whether the severity of the renal injury was related
to the declining renal nitric oxide system.
METHODS
Animals
Studies were conducted on 53 male Sprague-Dawley
(SD) rats (12 to 14 weeks old and 380 to 400 g body
weight when purchased from Harlan (Indianapolis, IN,
USA). Rats were allowed ad libitum access to tap water
and standard rat chow (24.4% protein mainly soy with
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some corn and wheat, 3.93 kcal/g). All rats had baseline
metabolic cage measurements and were then subjected
to either sham surgery or 5/6 A/I by removal of the right
kidney and infarction of 2/3 of the left kidney by ligation
of branches of the renal artery and assigned to the follow-
ing groups: group 1, sham-operated rats maintained on
regular rat chow and tap water (N  6) maintained for
4 weeks were controls for groups 3 and 6 (these rats
were studied at 2 to 6 weeks post-A/I); group 2, sham-
operated rats maintained on 0.225% NaCl in drinking
water throughout the follow-up and high protein diet
(40% protein, casein, 3.76 kcal/g) administered after 1
week of surgery (N  15) for a total of 18 to 21 days
were controls for groups 4 and 5; group 3, 5/6 A/I rats
maintained on normal water and food, sacrificed after
14 days of surgery (N  5); group 4, 5/6 A/I rats main-
tained on the same protocol as group 2, sacrificed 14
days after surgery (N  5); group 5, 5/6 A/I rats on the
same protocol as group 2, sacrificed at 18 to 21 days after
surgery (N  8); group 6, 5/6 A/I rats on normal water
and food, sacrificed after 4 to 6 weeks of surgery (N 
6); group 7, 5/6 A/I rats on normal water and food,
sacrificed 11 weeks after surgery (N  6); and group 8,
sham-operated rats on normal water and food, sacrificed
11 weeks after surgery (N  6), were controls for group
7. All surgical procedure was done using full sterile tech-
nique.
Metabolic cage
Twenty-four–hour urine was collected in metabolic
cages before surgery and just prior to sacrifice. When
rats were sacrificed, a blood sample was taken for plasma
creatinine and blood urea nitrogen (BUN) (Sigma Diag-
nostics, St. Louis, MO, USA) (Creatinine 1 Kit 555-A
and Urea Nitrogen 640-A). A thin section of cortex was
fixed for histology and kidneys were then separated into
cortex and medulla and stored at80C for later analysis.
Western blot
Western blot analysis was made as described pre-
viously [19]. Briefly, measurement was conducted on kid-
ney cortex (200 g total protein) and kidney medulla
(100 g total protein) for nNOS with a rabbit polyclonal
antibody (1:5000 dilution, 1-hour incubation) and sec-
ondary antibody, goat, antirabbit IgG-horseradish per-
oxidase (HRP) (1:3000 dilution, 1-hour incubation) (Bio-
Rad, Hercules, CA, USA) [20]. Membranes were stripped
and reprobed for eNOS (mouse monoclonal antibody)
(1:250 dilution, 1-hour incubation) (Transduction Labo-
ratories, Lexington, KY, USA) secondary antibody goat,
antimouse IgG-HRP conjugate (1:2000 dilution, 1-hour
incubation) (Transduction Laboratories). NOS protein
abundance was calculated as integrated optical density
(IOD) of nNOS or eNOS factored for Ponceau red stain
(total protein loaded) and for an internal standard and
expressed as a percent of the respective IOD control
value.
NOS activity
NOS activity was measured in groups 2 and 5, in the
soluble fraction of kidney cortex and medulla, by the con-
version of [3H]-l-arginine to [3H]-l-citrulline in. Briefly,
tissues were homogenized, ultracentrifuged, and super-
natants were collected. Endogenous arginine was re-
moved using Dowex resin and samples were run in the
presence of nonselective inhibitors, L-NMA (10 mmol/L)
and L-NAME (20 mmol/L). Data are expressed as pico-
moles of [3H]-l-arginine converted to [3H]-l-citrulline per
minute per mg protein. Details were given previously [19].
Histology was performed on kidneys fixed in 10%
formalin and then embedded in paraffin wax. Five-
micron sections were cut and stained with periodic acid-
Schiff (PAS) and examined, blinded for level of focal and
segmental glomerulosclerosis. One hundred glomeruli
from each kidney were evaluated and data were repre-
sented as % of glomeruli showing any level of injury.
The level of severity of injury was assessed using the 1
to 4 scoring system [11].
Statistics
Results are presented as mean  SEM. Data were
analyzed by unpaired t test, one-way analysis of variance
(ANOVA) followed by the Newman-Keuls test, regres-
sion analysis, and, for the morphologic data, the Kruskal-
Wallis and Pearson test for correlation. P  0.05 was
considered statistically significant.
RESULTS
The 24-hour urine protein excretion did not differ at
baseline between groups (overall average for all rats 
20  1 mg/24 hours) but increased markedly and in a
time-dependent manner in all A/I groups. In contrast,
sham-operated controls (groups 1, 2, and 8) showed only
a minimal change in urine protein excretion (P 0.05 vs.
baseline) over the observation period (Table 1). Plasma
creatinine level significantly increased in all A/I groups.
In group 3 rats (14 days post-A/I, normal diet), a moder-
ate elevation was observed, which was amplified by the
high salt/high protein regimen in groups 4 (14 days post-
A/I) and 5 (18 to 21days post-A/I). Groups 6 and 7 (4
to 6 weeks and 11 weeks post-A/I, normal diet) exhibited
further increases (versus group 3) (Table 1). As expected
creatinine clearance was reduced in A/I rats compared
to shams and BUN rose significantly in all A/I groups
(Table 1). As shown in Table 1, moderate glomerular
sclerosis developed as early as 2 weeks following A/I.
Longer postablation periods resulted in more severe glo-
merular sclerosis associated with tubular damage and
cell infiltration.
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Table 1. Blood and urine chemistry and extent of glomerulosclerosis (GS) in rats after ablation/infarction or in controls
Initial body Sacrifice body Urinary protein Plasma creatinine Creatinine clearance Blood urea
Group weight g weight g mg/24 hours mg/dL mL/min/kg nitrogen mg/dL GS %
1 SH 4 weeks 3552 3644 284 0.440.01 7.220.4 24.51.4 3.830.96
2 SH-HS-HP 18 to 4155 4247 253 0.570.03 NM 24.52 2.690.45
21 days
3 A/I 14 days 3513 30516 11932a 1.020.11d 3.190.33a,d,e 75.99.8c 23.63.03a,f
4 A/I-HS-HP 14 days 42710 3835 21446b 1.210.09a,d 1.980.1c 72.85.4c 35.62.87b,c,d
5 A/I-HS-HP 18 to 4194 36813 NM 1.360.10b,d NM 135.915.4b 48.083.13b
21 days
6 A/I 4 to 6 weeks 4196 38021 22042a 1.690.23a,d 1.960.37a,c 86.814.9c 39.676.11a,d
7 A/I 11 weeks 3851 42523 13643a 2.60.70a 1.250.36a 12134a 52.676.67a
8 SH 11 weeks 3843 4705 414a,d 0.390.03d 6.90.8d 171d 114a,d
Abbreviations are: SH, sham; A/I, ablation/infarction; HS, saline in the drinking water; HP, high protein diet; NM, not measured.
aP  0.01 vs. group 1; bP  0.05 vs. group 2; cP  0.05 vs. group 5; dP  0.05 vs. group 7; eP  0.05 vs. groups 4, 6, and 7; fP  0.05 vs. groups 4, 5, 6, and 7
Fig. 1. The relative neuronal nitric oxide synthase (nNOS) abundance
in renal cortex and medulla, expressed as % of the appropriate sham
mean, control integrated optical density (IOD) (100%) for all five
groups of rats subjected to 5/6 renal ablation/infarction (A/I) (groups
3 to 7). *P  0.05 vs. respective sham (100%).
As shown in Figure 1, the nNOS abundance in cortex
(expressed as % of the appropriate sham control value)
was not significantly reduced in group 3 but a decline
was detected in nNOS protein abundance (65% to 70%
below control) in all other A/I groups. Similarly, in the
medulla, nNOS abundance did not differ between sham
(group 1) and group 3, whereas a significant decrease
was seen in all other A/I groups (Fig. 1). Of note, in
order to facilitate the comparison with control, appro-
priate shams were run on every membrane with each
A/I group. Representative gels are shown in Figure 2.
Since the rate of progression in this 5/6 A/I model is
quite variable, we looked at the regression relationship
between plasma creatinine and renal nNOS abundance
for every individual animal. Renal medullary nNOS
abundance was relatively constant up to plasma creati-
nine values of 1 mg/dL (reflecting 60% loss of renal
function). With further increases in plasma creatinine, a
steep decrease was seen in medullary nNOS abundance
(r0.501, P 0.005). There was a similar relationship
in the renal cortex although with greater variability (r 
0.362, P  0.05).
Next, we evaluated the correlation between renal
nNOS abundance and glomerular damage. As shown in
Figure 3, the more severe the glomerular sclerosis, the
greater the decline in nNOS abundance in both cortex
and medulla. The correlation between glomerular dam-
age and decline in nNOS abundance was highly signifi-
cant in kidney cortex (r  0.678, P  0.001) and me-
dulla (r  0.722, P  0.001).
The “in vitro” NOS activity was measured in the solu-
ble fraction of both cortex and medulla from group 2
(sham, high salt/protein intake) and group 5 (A/I high
salt/protein intake). As shown in Figure 4, NOS activity
of both renal cortex and medulla was significantly re-
duced in rats with CRD (group 5). Since we assayed
only the soluble fraction (mainly nNOS and iNOS), this
underestimates the total NOS activity, by the membrane
bound fraction (mainly eNOS, see below).
In contrast to the nNOS, eNOS protein abundance was
more variable (Fig. 5). In renal cortex, eNOS increased
significantly in groups 3 and 6 versus shams, whereas no
difference was seen in groups 4, 5, and 7. In medulla,
eNOS protein abundance was significantly increased only
in group 3.
DISCUSSION
The main novel finding in this study is that in the model
of CRD induced by 5/6 A/I, nNOS protein abundance
declines in both renal cortex and medulla in parallel with
increasing glomerular damage and with decreasing renal
function. The “threshold” for a decline in nNOS protein
is when30% of the glomeruli are injured or a plasma
creatinine of 1 mg/dL is exceeded.
The renal mass reduction model has been extensively
studied as an animal model of CRD. In fact there are
two models, the 5/6 A (where the right kidney and the
poles of the left kidney are excised) and the 5/6 A/I model
where the two poles of the left kidney are infarcted by
ligation of branches of the renal artery. These models
differ in that an earlier, more profound hypertension
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Fig. 2. Representative Western blot gels show-
ing neuronal nitric oxide synthase (nNOS)
(A ) and endothelial nitric oxide synthase
(eNOS) (B ) of renal medulla (100 g per
sample). The positive control (CT) for
eNOS (10 g of bovine aortic endothelial cell
lysate) and nNOS (1 g of rat cerebellar ho-
mogenate) are shown in the final lane and the
molecular weight marker (MWM) in the first.
Fig. 3. Correlation between glomerular damage and relative neuronal
nitric oxide synthase (nNOS) abundance. (A ) % of the appropriate
sham mean in renal cortex for all rats studied. Symbols are: () 100%
cortical nNOS denote sham groups 1, 2, and 8; () group 3; (), group
4; () group 5; (	) group 6; and (
) group 7. r  0.678, P  0.0001.
(B ) % of the appropriate sham mean in renal medulla for all rats
studied. () 100% medullary nNOS denote groups 1, 2, and 8; ()
group 3; () group 4; () group 5; (	) group 6; and (
) group 7. r 
0.722, P  0.0001.
develops in the 5/6 A/I [21]. In addition, there are bound
to be small differences in the extent of renal mass reduc-
tion (using either method) between animals; there is a
clear strain difference in susceptibility to development
of CRD in response to reduction of renal mass [22], and
Fig. 4. “In vitro” nitric oxide synthase (NOS) activity (pmol L-arginine
converted to L-citrulline/min/mg protein) in the soluble fraction of renal
cortex and medulla in sham group 2 () and accelerated 5/6 ablation/
infarction (A/I) group 5 (]) rats. *P  0.05 between groups 2 and 5.
the development of the injury is rapidly progressive and
thus highly time dependent. Because of these concerns,
it is not always easy to compare results between different
laboratories. Accordingly, we have used the 5/6 A/I
model at multiple time points to investigate the impact
of evolving CRD on the renal NOS system.
There is convincing evidence that a decline in the “in
vitro” renal NOS activity occurs as CRD develops, due
to 5/6 A/I [4] and we have now confirmed this for the
accelerated A/I model at 18 to 21 days after surgery.
Since the NOS activity assay is conducted in vitro, in the
presence of excess substrate and required cofactors, this
gives an indication of the abundance/activity of the renal
NOS. The assay is conducted on the soluble fraction,
which presumably reflects the combined activity of the
cytosolic nNOS and iNOS isoforms. There is evidence
that the nonspecific distribution of NOS protein [deter-
mined from nicotinamide adenine dinucleotide phos-
phate (NADPH) diaphorase staining] is reduced in the
rat with 5/6 A/I [4] and in the vimentin knockout mouse
with 3/4 ablation of renal mass, which produces acute
renal failure and death within 72 hours [23]. Several
groups have reported declines in the abundance of the
iNOS protein in both 5/6 ablation and A/I in the rat [4,
15–17]. However, the iNOS protein abundance should
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Fig. 5. The relative endothelial nitric oxide synthase (eNOS) abun-
dance in renal cortex and medulla, expressed as % of the appropriate
sham mean, control integrated optical density (IOD) (100%) for all
five groups of rats subjected to 5/6 renal ablation/infarction (A/I)
(groups 3 to 7). *P  0.05 vs. respective sham (100%).
be low in the nonimmunologically stimulated kidney and
it is not clear what functional impact a further reduction
in abundance would have on regional renal nitric oxide
production. The nNOS is the most abundant renal NOS,
with primarily an epithelial distribution, in the macula
densa region of the cortex and in the inner medullary
collecting duct [24, 25]. The findings for abundance of
renal nNOS in the remnant kidney are more variable,
with a marked and early decline at 2 weeks post-5/6
ablation [5] as well as an increased abundance at 6 weeks
post-5/6 ablation [17] having been reported. In the pres-
ent study, we have consistently observed that the renal
nNOS abundance declines in CRD secondary to 5/6 renal
A/I once the plasma creatinine rises above 1 mg/dL
(normal for the rat is 0.4 to 0.5 mg/dL). Of note, our
2 weeks post-5/6 A/I rats fed regular chow and tap water
did not show a significant fall in nNOS protein (mean
plasma creatinine was 1.02 0.11 mg/dL), whereas accel-
eration of the CRD with high salt and protein intake
resulted in a larger rise in plasma creatinine and in
marked loss of renal nNOS protein at 14 days after 5/6
A/I. We then investigated the impact of further reduction
in renal function and found that the rate of decline in
renal nNOS abundance was very steep. This was also
reflected in Figure 1, since similar mean levels of reduc-
tion in cortical and medullary nNOS are seen in groups
4 to 7 despite increasing values of plasma creatinine. The
within-group variability in this model conceals the strong
correlation between histologic changes and the decline
of nNOS abundance, apparent when individual data
points are subject to regression analysis (Fig. 2).
Our findings agree qualitatively with the observations
of Roczniak et al [5] who observed a fall in renal nNOS
abundance post-5/6 ablation. However, this study re-
ported a decline at 2 weeks, whereas we did not see a
reduction in nNOS until after 2 weeks post-5/6 A/I, which
likely reflects a different time course in the two models.
These findings contrast with those of Vaziri et al [17]
who reported increased renal and brain nNOS activity
at 6 weeks post-5/6 ablation. In the present study, we
used a rabbit polyclonal antibody recognizing amino
acids 1-231 at the N terminal [20], whereas both other
groups used Transduction Laboratory antibodies, which
recognize amino acids 1095-1289 at the C terminal. Nev-
ertheless, since our findings of reduced renal nNOS pro-
tein are in accord with Roczniak et al [5], the primary
antibody employed is unlikely to be an issue. In addition
to nNOS protein abundance, nNOS activity can also be
regulated by a protein inhibitor of the nNOS (PIN) [26].
PIN colocalizes with nNOS in the inner medulla, but not
in the primary cortical site of nNOS distribution, the
macula densa, and Roczniak et al have reported marked
increases in PIN abundance in inner medulla at 2 weeks
post-5/6 ablation [27]. Thus, in vivo renal nNOS activity
is likely to be markedly reduced in the remnant kidney,
particularly in medulla.
What is the functional significance of a decline in renal
nNOS activity? The macula densa nNOS provides a
“brake” on tubuloglomerular feedback (TGF)–induced
afferent arteriolar constriction [28]. This effect can be
demonstrated with acute local nNOS inhibition [28], but
in the nNOS knockout mouse [29, 30] and in the rat with
4 weeks of nNOS inhibition [31] TGF responsiveness is
normal, suggesting compensation during chronic nNOS
removal. However, 4 weeks of chronic systemic nNOS
inhibition leads to hypertension without a fall in glomer-
ular filtration rate (GFR) [31], while chronic local, inner
medullary nNOS inhibition also creates a salt dependent
hypertension [24]. Thus, loss of inner medullary nNOS
activity may play a key role in the progression of the
CRD, via potentiation of the accompanying hyperten-
sion.
The regulation of nNOS protein abundance is complex
[32] and it is not clear what signal causes reduction in
nNOS protein abundance in the 5/6 renal A/I model.
However, the signal is likely to be associated with the
general injury process, rather than specific model, since
reduced renal nNOS is also seen in CRD secondary
to 5/6 ablation [5], chronic glomerulonephritis [6], age-
dependent damage in the aging male [33], and in ad-
vanced kidney disease in a model of type 2 diabetes
(Erdely et al, unpublished data, 2003). Most likely, high
BUN is not responsible since 7 days of severely uremic
levels of BUN in the rat had no impact on renal NOS
activity or nNOS protein abundance [19]. There is a well-
documented angiotensin II dependence of progression
of CRD and while angiotensin II type 1 blockade was
without effect on the decreased medullary nNOS seen at
2 weeks post-5/6 ablation, a partial restoration of cortical
nNOS was seen [5]. However, acute and chronic angio-
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tensin II infusion lead to either no change or increased
cortical NOS activity and nNOS protein abundance [34, 35]
and nNOS and renin are generally changed in parallel [36],
which eliminates a direct angiotensin II–mediated inhibi-
tory effect in the present study. At present, the precise
trigger to decreased renal nNOS remains unknown.
The impact of renal disease on eNOS protein abun-
dance in progression of CRD is less clear. Some investi-
gators found decreased eNOS expression in renal reduc-
tion models of CRD [4, 15, 16], while in the present study
we find either increases or no change in both cortical
and medullary eNOS protein at different stages of the
evolving renal disease. We have also observed that no
change occurs in renal eNOS abundance in the chronic
glomerulonephritis model of CRD [6] and that the fall
seen in the aging male rat kidney is delayed relative to the
decline in nNOS [33]. Of course, total eNOS abundance
measured by Western blot on kidney homogenates can-
not give information on the local intrarenal distribution
of the eNOS and integrity of the microvascular endothe-
lium. Indeed, in the rapidly progressing 5/6 ablation 
chronic NOS inhibition model, the glomerular and peri-
tubular endothelium is diminished while the preglomeru-
lar endothelium is preserved and possibly even hypertro-
phied [18]. In addition, NOS protein abundance is just
one contributor to the overall NOS activity. The 5/6
ablation model of CRD is associated with increased reac-
tive oxygen species [17] and a high oxidant state is known
to switch both nNOS and eNOS from nitric oxide to
superoxide anion generators [37, 38].
CONCLUSION
Renal NOS activity and nNOS protein abundance are
inversely correlated with developing kidney damage in
the 5/6 A/I model of CRD. While the precise stimulus
remains unknown, there seems to be a “threshold” effect
of decreasing renal function/increased renal injury that
triggers a steep decline in nNOS protein. It is not possible
from these studies to determine whether renal nNOS
abundance/activity falls as a passive consequence of kid-
ney damage, or whether this also contributes to develop-
ment of the injury.
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